Europe Immunodiagnostics Market Forecast to 2030

Europe Immunodiagnostics Market Forecast to 2030 – Regional Analysis – by Product (Enzyme-Linked Immunosorbent Assays (ELISA), Chemiluminescence Immunoassays (CLIA), Radioimmunoassays (RIA), and Others), By Clinical Indication (Infectious Diseases, Hepatitis+HIV, Endocrinology, Gastrointestinal, Metabolics, and Others), and End User (Hospitals, Clinics, Diagnostic Laboratories, Academic & Research Institutes, and Others)

Send Enquiry
Item ID: BMIRE00027867 Category: Tags: , ,

$2,100$3,500

Description

The Europe immunodiagnostics market is expected to grow from US$ 6,131.85 million in 2023 to US$ 10,098.03 million by 2030. It is estimated to grow at a CAGR of 7.4% from 2023 to 2030.

Increasing Prevalence of Infectious Diseases Drive Europe Immunodiagnostics Market

The diagnosis and management of several ever-growing infectious diseases caused by infectious agents such as viruses, fungi, bacteria, parasites, or their toxic products are surging number of prescriptions for immunodiagnostics tests, e.g., complement fixation, precipitation tests, agglutination tests, line blot assays, Western blot assays, enzyme immunoassays (EIA), and immunofluorescence tests. Human immunodeficiency virus (HIV) continues to be a major public health issue worldwide. Further, tuberculosis (TB), COVID-19, and other hospital-acquired infections (HAIs) require immunodiagnostics tests.

• TB has been the 13th leading cause of death and the second-leading infectious killer after COVID-19. In 2020, 1.5 million people died from TB and affected an estimated 10 million people, comprising 5.6 million males, 3.3 million females, and 1.1 million children globally.

• According to Worldometer, millions of deaths were reported worldwide due to the COVID-19 pandemic. It strained healthcare systems and increased the need for immunodiagnostics tests.

Diagnostics play a vital role in determining suitable medical treatments. Immunodiagnostics help diagnose diseases that severely impact the immune system. Hence, the rising prevalence of infectious diseases lead to the surging demand for immunodiagnostics products.

Europe Immunodiagnostics Market Overview
The huge geriatric population is significantly driving the market for immunodiagnostics in Germany. According to the UN population data, 1 out of 20 Germans is aged above 80 years, and the number is expected to increase to 6 out of 20 by 2050. The risk of developing chronic diseases, such as cardiovascular diseases (CVDs), diabetes, and neurovascular disorders, increases with age. According to the estimates of the German Centre for Cancer Registry Data (ZfKD) published by the Robert Koch Institute in September 2023, in Germany, 502,655 people had cancer in 2019, among which 234,925 were women and 267,730 were men. It is estimated that the prevalence of cancer is likely to continue owing to lifestyle changes, obesity, unhealthy habits, and more. The most common cancers in Germany are breast, prostate, colorectum (large bowel), lung, and bladder cancer. These five cancer types accounted for about 57% of all new cancer diagnoses in Germany. Thus, the increasing prevalence of cancer is likely to propel the demand for immunodiagnostics.
Germany is the leading medical biotech nation in the world after the US. In 2020, the German biotechnology sector grew significantly compared to the pre-COVID year 2018. The positive market trend has accelerated in the last few years in some areas; and according to the OECD-compliant survey by BIOCOM, the German biotechnology industry’s turnover increased by almost 50% in 2020. The presence of long-established companies and the emergence of start-ups affirmed the industrial strength. Industry, government, and research sectors thrive on strong market foundations. With many European biotech companies, world-class research infrastructure, and internationally renowned scientists, Germany has firmly established itself as an international medical biotechnology hub. German biotech companies emerged as global leaders in mRNA technologies by introducing the first COVID-19 test and vaccination, approved by the European Medicines Agency. Such developments have encouraged enhanced technological advancements for immunodiagnostics. Thus, the rising biotechnology sector will likely boost the country’s immunodiagnostics market.

Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)

Europe Immunodiagnostics Market Segmentation

The Europe immunodiagnostics market is segmented into product, clinical indication, end user, and country.

Based on product, the Europe immunodiagnostics market is segmented into enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassays (RIA), and others. In 2023, the enzyme-linked immunosorbent assays (ELISA) segment registered the largest share in the Europe immunodiagnostics market. The chemiluminescence immunoassays (CLIA) segment is further segmented into vitamin D assay market, HIV detection market, HIV ag/ab combo assay market, and other tests.

Based on clinical indication, the Europe immunodiagnostics market is segmented into infectious diseases, hepatitis+hiv, endocrinology, gastrointestinal, metabolics, and others. In 2023, the infectious diseases segment registered the largest share in the Europe immunodiagnostics market. The infectious diseases segment is further segmented into COVID-19, tuberculosis, lyme, infection management, zika, treponema, torch, measles and mumps, VZV, and EBV. The endocrinology segment is further segmented into hypertension, growth, diabetes, thyroid, and reproductive endocrinology.

Based on end user, the Europe immunodiagnostics market is segmented into hospitals, clinics, diagnostic laboratories, academic & research institutes, and others. In 2023, the hospitals segment registered the largest share in the Europe immunodiagnostics market.

Based on country, the Europe immunodiagnostics market is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. In 2023, Germany segment registered the largest share in the Europe immunodiagnostics market.

Abbott Laboratories; bioMerieux SA; Danaher Corp; DiaSorin SpA; F. Hoffmann-La Roche Ltd; PerkinElmer Inc; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Siemens Healthcare GmbH; Svar Life Science AB; and Thermo Fisher Scientific Inc are some of the leading companies operating in the Europe immunodiagnostics market.

Summary Info

Industry:

Number of pages:

Pricing options:

, ,

Publishing status:

Geographical coverage:

Year of Publication:

At 7.4% CAGR, the Europe Immunodiagnostics Market is speculated to be worth US$ 10,098.03 million by 2030, saysthe research team

According tothe research team’ Research, the Europe immunodiagnostics market was valued at US$ 6,131.85 million in 2023 and is expected to reach US$ 10,098.03 million by 2030, registering a CAGR of 7.4% from 2023 to 2030. Growing use of point-of-care immunodiagnostics and increasing prevalence of infectious diseases are the critical factors attributed to the Europe immunodiagnostics market expansion.
Point-of-care testing (POCT) has become critical to patient-centric healthcare due to the need for rapid diagnostic results to determine accurate and faster treatments. A shift from centralized point-of-care testing to decentralized testing has resulted in easy access to these diagnostics. Immunoassay testing helps monitor chronic conditions and detect pathogens, such as bacteria and viruses. Advanced point-of-care devices enable rapid screening of up to three components from a single sample. Also, the point-of-care diagnostics (POCD) inclined toward mobile healthcare (mH) smart devices could revolutionize personalized healthcare monitoring and management, paving the way for next-generation POCTs. The management of infectious diseases can be significantly improved by POCTs, particularly in developing countries where access to timely medical care is challenging and healthcare infrastructure is outdated and sparse. Additionally, the technologically developed diagnostic kits leading to fewer manual errors propel the Europe immunodiagnostics market. Several market players are developing innovative immunodiagnostic products. For instance, Thermo Fisher Scientific has developed immunodiagnostic products such as enzyme-linked immunoassay (ELISA) reagents and buffers, antibodies and detection probes, linking mechanisms, blocking buffers and detergents, detection substrates, and capture surfaces, as well as services such as bioconjugation and detection. Further, in September 2020, Roche launched the SARS-CoV-2 Rapid Antigen Test, which is used in POC settings to help healthcare professionals identify the infection within 15 minutes in people suspected of carrying the virus.

In April 2021, DiaSorin introduced the LIAISON IQ, a new immunodiagnostic Point-of-Care (POC) reader, and the LIAISON QuickDetect COVID TrimericS Ab test, developed with Lumos Diagnostics for countries accepting the CE Mark. Using a fingerstick of human capillary blood, this test for the LIAISON IQ identifies specific IgG antibodies against SARS-CoV-2 Spike Protein in 10 minutes. Likewise, the use of immunodiagnostics in cancer treatment is increasing. In oncology, an immunodiagnostic test can confirm the presence of a solid tumor by detecting known tumor-associated antigens or antibodies. These advantages and indications are driving the Europe immunodiagnostics market.

On the contrary, inadequate reimbursement scenario hurdles the growth of Europe immunodiagnostics market.

Based on product, the Europe immunodiagnostics market is segmented into enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassays (RIA), and others. The enzyme-linked immunosorbent assays (ELISA) segment held 55.3% share of Europe immunodiagnostics market in 2023, amassing US$ 3,393.40 million. It is projected to garner US$ 5,523.28 million by 2030 to expand at 7.2% CAGR during 2023–2030. The chemiluminescence immunoassays (CLIA) segment is further segmented into vitamin D assay market, HIV detection market, HIV ag/ab combo assay market, and other tests.

Based on clinical indication, the Europe immunodiagnostics market is segmented into infectious diseases, hepatitis HIV, endocrinology, gastrointestinal, metabolics, and others. The infectious diseases segment held 44.9% share of Europe immunodiagnostics market in 2023, amassing US$ 2,755.78 million. It is projected to garner US$ 4,711.65 million by 2030 to expand at 8.0% CAGR during 2023–2030. The infectious diseases segment is further segmented into COVID-19, tuberculosis, lyme, infection management, zika, treponema, torch, measles and mumps, VZV, and EBV. The endocrinology segment is further segmented into hypertension, growth, diabetes, thyroid, and reproductive endocrinology.

Based on end user, the Europe immunodiagnostics market is segmented into hospitals, clinics, diagnostic laboratories, academic & research institutes, and others. The hospitals segment held 43.3% share of Europe immunodiagnostics market in 2023, amassing US$ 2,654.93 million. It is projected to garner US$ 4,295.46 million by 2030 to expand at 7.1% CAGR during 2023–2030.

Based on country, the Europe immunodiagnostics market is segmented into Based on country, the Europe immunodiagnostics market is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 29.3% share of Europe immunodiagnostics market in 2023. It was assessed at US$ 1,799.08 million in 2023 and is likely to hit US$ 2,885.01 million by 2030, exhibiting a CAGR of 7.0% during 2023–2030.

Key players operating in the Europe immunodiagnostics market report Abbott Laboratories; bioMerieux SA; Danaher Corp; DiaSorin SpA; F. Hoffmann-La Roche Ltd; PerkinElmer Inc; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Siemens Healthcare GmbH; Svar Life Science AB; and Thermo Fisher Scientific Inc, among others.

– Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific frozen waffles market.
– Highlights key business priorities in order to assist companies to realign their business strategies.
– the key findings and recommendations highlight crucial progressive industry trends in Asia Pacific frozen waffles market, thereby allowing players across the value chain to develop effective long-term strategies.
– develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
– Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.
– Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

TABLE OF CONTENTS

1. Introduction
1.1 Scope of the Study
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Immunodiagnostics Market – by Product
1.3.2 Europe Immunodiagnostics Market – by Clinical Indication
1.3.3 Europe Immunodiagnostics Market – by End User
1.3.4 Europe Immunodiagnostics Market – by Country
2. Europe Immunodiagnostics Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Immunodiagnostics Market – Market Landscape
4.1 Overview
4.2 Europe PEST Analysis
4.3 Expert’s Opinion
5. Europe Immunodiagnostics Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Infectious Diseases
5.1.2 Growing Use of Point-of-Care Immunodiagnostics
5.2 Market Restraints
5.2.1 Inadequate Reimbursement Scenario
5.3 Market Opportunities
5.3.1 Rising Focus on R&D Investment and Expansion by Key Players
5.4 Future Trends
5.4.1 Technological Advancements in Immunodiagnostics
5.5 Impact Analysis
6. Immunodiagnostics Market – Europe Analysis
6.1 Europe Immunodiagnostics Market Revenue Forecast and Analysis
7. Europe Immunodiagnostics Market Analysis – by Product
7.1 Overview
7.2 Europe Immunodiagnostics Market, By Product, 2022 & 2030 (%)
7.3 Enzyme-linked Immunosorbent Assays (ELISA)
7.3.1 Overview
7.3.2 Enzyme-linked Immunosorbent Assays (ELISA): Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.4 Chemiluminescence Immunoassays (CLIA)
7.4.1 Overview
7.4.2 Chemiluminescence Immunoassays (CLIA): Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.4.3 Vitamin D Assay
7.4.3.1 Overview
7.4.3.2 Vitamin D Assay: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.4.4 HIV Detection
7.4.4.1 Overview
7.4.4.2 HIV Detection: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.4.5 HIV Ag/Ab Combo assay
7.4.5.1 Overview
7.4.5.2 HIV Ag/Ab Combo Assay: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.4.6 Other Tests
7.4.6.1 Overview
7.4.6.2 Other Tests: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.5 Radioimmunoassays (RIA)
7.5.1 Overview
7.5.2 Radioimmunoassays (RIA): Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8. Europe Immunodiagnostics Market Analysis – Clinical Indication
8.1 Overview
8.2 Europe Immunodiagnostics Market Share by Clinical Indication – 2022 & 2030 (%)
8.3 Infectious Diseases:
8.3.1 Overview
8.3.2 Infectious Diseases: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.1 COVID-19
8.3.2.1.1 Overview
8.3.2.1.2 COVID-19: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.2 Tuberculosis
8.3.2.2.1 Overview
8.3.2.2.2 Tuberculosis: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.3 Lyme
8.3.2.3.1 Overview
8.3.2.3.2 Lyme: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.4 Infection Management
8.3.2.4.1 Overview
8.3.2.4.2 Infection Management: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.5 Zika
8.3.2.5.1 Overview
8.3.2.5.2 Zika: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.6 Treponema
8.3.2.6.1 Overview
8.3.2.6.2 Treponema: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.7 TORCH
8.3.2.7.1 Overview
8.3.2.7.2 TORCH: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.8 Measles and Mumps
8.3.2.8.1 Overview
8.3.2.8.2 Measles and Mumps: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.9 VZV
8.3.2.9.1 Overview
8.3.2.9.2 VZV: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.3.2.10 EBV
8.3.2.10.1 Overview
8.3.2.10.2 EBV: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.4 Hepatitis+HIV:
8.4.1 Overview
8.4.2 Hepatitis+HIV: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.5 Gastrointestinal
8.5.1 Overview
8.5.2 Gastrointestinal: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.6 Metabolic Disorders
8.6.1 Overview
8.6.2 Metabolics: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7 Endocrinology
8.7.1 Overview
8.7.2 Endocrinology: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7.3 Hypertension
8.7.3.1 Overview
8.7.3.2 Hypertension: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7.4 Growth
8.7.4.1 Overview
8.7.4.2 Growth: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7.5 Diabetes
8.7.5.1 Overview
8.7.5.2 Diabetes: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7.6 Thyroid
8.7.6.1 Overview
8.7.6.2 Thyroid: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7.7 Reproductive Endocrinology
8.7.7.1 Overview
8.7.7.2 Reproductive Endocrinology: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.8 Others
8.8.1 Overview
8.8.2 Others: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9. Europe Immunodiagnostics Market Analysis – End User
9.1 Overview
9.2 Europe Immunodiagnostics Market Share by End User – 2022 & 2030 (%)
9.3 Hospitals
9.3.1 Overview
9.3.2 Hospitals: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.4 Clinics
9.4.1 Overview
9.4.2 Clinics: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.5 Diagnostic Laboratories
9.5.1 Overview
9.5.2 Diagnostic Laboratories: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.6 Academic and Research Institutes
9.6.1 Overview
9.6.2 Academic and Research Institutes: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.7 Others
9.7.1 Overview
9.7.2 Others: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
10. Europe Immunodiagnostics Market – Revenue and Forecast to 2030 – Country Analysis
10.1 Overview
10.1.1.1 UK: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.1 Overview
10.1.1.1.2 UK: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.3 UK: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.1.1.1.3.1 UK: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.4 UK: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.4.1 UK: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.4.2 UK: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.1.1.1.5 UK: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.1.1.2 Germany: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.1 Overview
10.1.1.2.2 Germany: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.3 Germany: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.1.1.2.3.1 Germany: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.4 Germany: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.4.1 Germany: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.4.2 Germany: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.5 Germany: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.1.1.3 France: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.1 Overview
10.1.1.3.2 France: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.3 France: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.1.1.3.3.1 France: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.4 France: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.4.1 France: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.4.2 France: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.5 France: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.1.1.4 Italy: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.1 Overview
10.1.1.4.2 Italy: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.3 Italy: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.1.1.4.3.1 Italy: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.4 Italy: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.4.1 Italy: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.4.2 Italy: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.5 Italy: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.1.1.5 Spain: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.5.1 Overview
10.1.1.5.2 Spain: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.5.3 Spain: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.1.1.5.3.1 Spain: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.1.1.5.4 Spain: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.1.1.5.4.1 Spain: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.1.1.5.4.2 Spain: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.1.1.5.5 Spain: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
10.1.1.6 Rest of Europe: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.6.1 Overview
10.1.1.6.2 Rest of Europe: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
10.1.1.6.3 Rest of Europe: Immunodiagnostics Market, by Product, 2020–2030 (US$ Million)
10.1.1.6.3.1 Rest of Europe: Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
10.1.1.6.4 Rest of Europe: Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
10.1.1.6.4.1 Rest of Europe: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
10.1.1.6.4.2 Rest of Europe: Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
10.1.1.6.5 Rest of Europe: Immunodiagnostics Market, by End User, 2020–2030 (US$ Million)
11. Europe Immunodiagnostics Market –Industry Landscape
11.1 Overview
11.2 Inorganic Growth Strategies
11.2.1 Overview
11.3 Organic Growth Strategies
11.3.1 Overview
12. Company Profiles
12.1 Abbott Laboratories
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 F. Hoffmann-La Roche Ltd
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 DiaSorin SpA
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Danaher Corp
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Thermo Fisher Scientific Inc
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 PerkinElmer Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 bioMerieux SA
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Svar Life Science AB
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Siemens Healthcare GmbH
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About
13.2 Glossary of Terms

LIST OF TABLES

Table 1. UK Immunodiagnostics Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 2. UK Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
Table 3. UK Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
Table 4. UK Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
Table 5. UK Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
Table 6. UK Immunodiagnostics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 7. Germany Immunodiagnostics Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 8. Germany Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
Table 9. Germany Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
Table 10. Germany: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
Table 11. Germany Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
Table 12. Germany Immunodiagnostics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 13. France Immunodiagnostics Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 14. France Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
Table 15. France Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
Table 16. France: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
Table 17. France Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
Table 18. France Immunodiagnostics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 19. Italy Immunodiagnostics Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 20. Italy Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
Table 21. Italy Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
Table 22. Italy: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
Table 23. Italy Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
Table 24. Italy Immunodiagnostics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 25. Spain Immunodiagnostics Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 26. Spain Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
Table 27. Spain Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
Table 28. Spain: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
Table 29. Spain Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
Table 30. Spain Immunodiagnostics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 31. Rest of Europe Immunodiagnostics Market, by Product – Revenue and Forecast to 2030 (US$ Million)
Table 32. Rest of Europe Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)– Revenue and Forecast to 2030 (US$ Million)
Table 33. Rest of Europe Immunodiagnostics Market, by Clinical Indication – Revenue and Forecast to 2030 (US$ Million)
Table 34. Rest of Europe: Immunodiagnostics Market, by Infectious Diseases – Revenue and Forecast to 2030 (US$ Million)
Table 35. Rest of Europe Immunodiagnostics Market, by Endocrinology – Revenue and Forecast to 2030 (US$ Million)
Table 36. Rest of Europe Immunodiagnostics Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 37. Recent Inorganic Growth Strategies in the Europe immunodiagnostics market
Table 38. Recent Organic Growth Strategies in the Europe immunodiagnostics market
Table 39. Glossary of Terms, Europe Immunodiagnostics Market

LIST OF FIGURES

Figure 1. Europe Immunodiagnostics Market Segmentation
Figure 2. Europe Immunodiagnostics Market, by Country
Figure 3. Europe Immunodiagnostics Market Overview
Figure 4. Enzyme-Linked Immunosorbent Assays (ELISA) Segment Held Largest Share of Product Segment in Europe Immunodiagnostics Market
Figure 5. The UK Expected to Show Remarkable Growth During Forecast Period
Figure 6. Europe: PEST Analysis
Figure 7. Experts’ Opinion
Figure 8. Europe Immunodiagnostics Market: Impact Analysis of Drivers and Restraints
Figure 9. Europe Immunodiagnostics Market – Revenue Forecast and Analysis – 2021–2030
Figure 10. Europe Immunodiagnostics Market, by Product, 2022 & 2030 (%)
Figure 11. Enzyme-linked Immunosorbent Assays (ELISA): Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 12. Chemiluminescence Immunoassays (CLIA): Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 13. Vitamin D Assay: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 14. HIV Detection: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 15. HIV Ag/Ab Combo Assay: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 16. Other Tests: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 17. Radioimmunoassays (RIA): Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 18. Others: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 19. Europe Immunodiagnostics Market Share by Clinical Indication – 2022 & 2030 (%)
Figure 20. Infectious Diseases: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 21. COVID-19: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 22. Tuberculosis: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 23. Lyme: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 24. Infection Management: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 25. Zika: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 26. Treponema: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 27. TORCH: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 28. Measles and Mumps: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 29. VZV: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 30. EBV: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 31. Hepatitis+HIV: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 32. Gastrointestinal: Europe Immunodiagnostics Market Revenue and Forecasts to 2030 (US$ Million)
Figure 33. Metabolics: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 34. Endocrinology: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 35. Hypertension: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 36. Growth: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 37. Diabetes: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 38. Thyroid: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 39. Reproductive Endocrinology: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 40. Endocrinology: Europe Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 41. Europe Immunodiagnostics Market Share by End User – 2022 & 2030 (%)
Figure 42. Hospitals: Europe Immunodiagnostics Market Revenue and Forecasts to 2030 (US$ Million)
Figure 43. Clinics: Europe Immunodiagnostics Market Revenue and Forecasts To 2030 (US$ Million)
Figure 44. Diagnostic Laboratories: Europe Immunodiagnostics Market Revenue and Forecasts to 2030 (US$ Million)
Figure 45. Academic and Research Institutes: Europe Immunodiagnostics Market Revenue and Forecasts to 2030 (US$ Million)
Figure 46. Others: Europe Immunodiagnostics Market Revenue and Forecasts to 2030 (US$ Million)
Figure 47. Europe: Immunodiagnostics Market, by Key Country – Revenue (2022) (US$ Million)
Figure 48. Europe: Immunodiagnostics Market, by Country, 2022 & 2030 (%)
Figure 49. UK: Immunodiagnostics market – Revenue and Forecast to 2030 (US$ Million)
Figure 50. Germany: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 51. France: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 52. Italy: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 53. Spain: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)
Figure 54. Rest of Europe: Immunodiagnostics Market – Revenue and Forecast to 2030 (US$ Million)

The List of Companies – Europe Immunodiagnostics Market

– Abbott Laboratories
– bioMerieux SA
– Danaher Corp
– DiaSorin SpA
– F. Hoffmann-La Roche Ltd
– PerkinElmer Inc
– Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
– Siemens Healthcare GmbH
– Svar Life Science AB
– Thermo Fisher Scientific Inc

Reviews

There are no reviews yet.

Be the first to review “Europe Immunodiagnostics Market Forecast to 2030”